[go: up one dir, main page]

SG10201909638UA - Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules - Google Patents

Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules

Info

Publication number
SG10201909638UA
SG10201909638UA SG10201909638UA SG10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA
Authority
SG
Singapore
Prior art keywords
genetically modified
mhc
molecules
major histocompatibility
histocompatibility complex
Prior art date
Application number
Inventor
Lynn Macdonald
Andrew Murphy
Naxin Tu
Cagan Gurer
Vera Voronina
Sean Stevens
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201909638UA publication Critical patent/SG10201909638UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) II MOLECULES The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II  and  polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided. [No Figure]
SG10201909638U 2011-10-28 2012-10-26 Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules SG10201909638UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552584P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
SG10201909638UA true SG10201909638UA (en) 2019-11-28

Family

ID=47430036

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201400938UA SG11201400938UA (en) 2011-10-28 2012-10-26 Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
SG10201510056SA SG10201510056SA (en) 2011-10-28 2012-10-26 Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
SG10201909638U SG10201909638UA (en) 2011-10-28 2012-10-26 Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201400938UA SG11201400938UA (en) 2011-10-28 2012-10-26 Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
SG10201510056SA SG10201510056SA (en) 2011-10-28 2012-10-26 Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules

Country Status (25)

Country Link
US (7) US8847005B2 (en)
EP (4) EP4052572B8 (en)
JP (2) JP6285361B2 (en)
KR (2) KR101926442B1 (en)
CN (3) CN108707608A (en)
AU (4) AU2012327205B2 (en)
BR (1) BR112014009941B1 (en)
CA (1) CA2852962C (en)
CY (3) CY1119283T1 (en)
DK (3) DK3272214T3 (en)
ES (3) ES2774488T3 (en)
HR (3) HRP20171327T1 (en)
HU (2) HUE034374T2 (en)
IL (3) IL231895B (en)
IN (1) IN2014CN03892A (en)
LT (3) LT2770822T (en)
MX (2) MX379060B (en)
PL (3) PL3590332T3 (en)
PT (3) PT3272214T (en)
RS (3) RS63220B1 (en)
RU (1) RU2660564C2 (en)
SG (3) SG11201400938UA (en)
SI (3) SI3590332T1 (en)
SM (3) SMT202200205T1 (en)
WO (1) WO2013063340A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065730A3 (en) 2006-04-26 2012-09-19 L-3 Communications Security and Detection Systems, Inc. Multi-source surveillance systems
RU2634417C2 (en) 2011-10-28 2017-10-26 Регенерон Фармасьютикалс, Инк. Humanized il-6 and il-6 receptor
CA2852962C (en) 2011-10-28 2022-05-03 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
PT2958938T (en) * 2013-02-20 2019-07-23 Regeneron Pharma Mice expressing humanized t-cell co-receptors
CN110192541B (en) 2013-02-22 2022-02-18 瑞泽恩制药公司 Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2903025C (en) * 2013-03-11 2025-10-07 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
SMT202300287T1 (en) 2013-09-23 2023-11-13 Regeneron Pharma Non-human animals having a humanized signal-regulatory protein gene
RU2674910C2 (en) * 2013-10-15 2018-12-13 Регенерон Фармасьютикалс, Инк. Humanised il-15 animals
SG11201603360QA (en) 2013-11-19 2016-05-30 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
HUE051088T2 (en) 2014-04-08 2021-03-01 Regeneron Pharma Non-human animals having humanized fc-gamma receptors
NO2785538T3 (en) 2014-05-07 2018-08-04
SG10201811116UA (en) 2014-06-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
KR20170083534A (en) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 Chimeric antigen receptors
SI3689140T1 (en) 2014-11-24 2022-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized cd3 complex
PL3086637T3 (en) 2014-12-05 2019-09-30 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS HAVING A HUMANIZED GEN OF DIFFERENTIAL COMPLEX 47
LT3230320T (en) 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
WO2016164492A2 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
CN108779159B (en) * 2016-02-04 2022-12-30 瑞泽恩制药公司 Non-human animals with engineered ANGPTL8 genes
WO2017151453A1 (en) 2016-02-29 2017-09-08 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
AU2017272337C1 (en) 2016-06-03 2024-02-29 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11202002456WA (en) 2017-11-30 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized trkb locus
DK3772927T3 (en) 2018-03-24 2025-02-17 Regeneron Pharma Genetically modified mice or rats for generating therapeutic antibodies against peptide-MHC complexes, method of preparation and uses thereof
KR20250121150A (en) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 Humanized rodents for testing therapeutic agents
AU2019308205B2 (en) 2018-07-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
CN114585744A (en) * 2019-10-22 2022-06-03 纽约市哥伦比亚大学理事会 Transgenic pigs, methods of making and uses thereof, and methods of making mice with human immune system
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma Peptide-mhc ii protein constructs and uses thereof
CN116981357A (en) 2021-03-31 2023-10-31 瑞泽恩制药公司 Genetically modified mice containing humanized cellular immune system components with improved TCRB repertoire diversity
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
CN119947583A (en) 2022-09-22 2025-05-06 瑞泽恩制药公司 Genetically modified mice expressing components of the human cellular immune system
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950707B1 (en) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
JP2000512127A (en) 1996-03-05 2000-09-19 ザ スクリップス リサーチ インスティトゥート Recombinant encoding a T cell receptor specific for human HLA-restricted tumor antigen
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ATE423789T1 (en) 1997-09-16 2009-03-15 Univ Oregon Health & Science RECOMBINANT MHC MOLECULES WHICH ARE USEFUL FOR THE MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
IL138579A0 (en) * 1998-03-30 2001-10-31 Res Dev Foundation Corticotropin releasing factor receptor 1-deficient mice
AU1023401A (en) 1999-10-12 2001-04-23 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7067308B1 (en) * 2000-03-28 2006-06-27 Bioagri Corporation Vector for genetically modifying non-human animals
WO2002000933A2 (en) 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002047474A1 (en) 2000-12-13 2004-04-15 住友製薬株式会社 HLA-A24 expressing transgenic animals and uses thereof
US20030093818A1 (en) 2000-12-19 2003-05-15 Belmont Heather J. Transgenic animals comprising a humanized immune system
FR2827302B1 (en) * 2001-07-13 2003-10-10 Genoway TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (en) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Recombinant vaccines and their use
WO2005085438A1 (en) 2004-03-09 2005-09-15 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
DK1802193T3 (en) 2004-10-19 2014-06-10 Regeneron Pharma Method of producing a homozygous mouse for genetic modification
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
US20090271884A1 (en) 2008-03-07 2009-10-29 Regeneron Pharmaceuticals, Inc. ES Cell-Derived Mice From Diploid Host Embryo Injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
CN101695587B (en) * 2009-10-21 2012-08-29 上海中山医疗科技发展公司 Method for preparing endothelial progenitor cell capturing bracket for gene modification and regulation
JP2013538555A (en) 2010-07-15 2013-10-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド An isolated high affinity entity with T cell receptor-like specificity for a natural complex of MHC class II and glutamate decarboxylase (GAD) autoantigenic peptide
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CA2852962C (en) 2011-10-28 2022-05-03 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
PT2958938T (en) 2013-02-20 2019-07-23 Regeneron Pharma Mice expressing humanized t-cell co-receptors
CN110192541B (en) 2013-02-22 2022-02-18 瑞泽恩制药公司 Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2903025C (en) 2013-03-11 2025-10-07 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
WO2016164492A2 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals

Also Published As

Publication number Publication date
AU2021200438B2 (en) 2023-11-02
HRP20200305T1 (en) 2020-06-12
DK3590332T3 (en) 2022-05-23
US20150040253A1 (en) 2015-02-05
WO2013063340A1 (en) 2013-05-02
EP2770822A1 (en) 2014-09-03
ES2640241T3 (en) 2017-11-02
EP3590332B1 (en) 2022-02-23
JP2014532411A (en) 2014-12-08
EP2770822B9 (en) 2019-12-11
EP4052572B1 (en) 2025-11-26
ES2774488T3 (en) 2020-07-21
EP4052572C0 (en) 2025-11-26
CN108707608A (en) 2018-10-26
US11219195B2 (en) 2022-01-11
IL260209A (en) 2018-07-31
CY1122700T1 (en) 2021-03-12
HRP20171327T1 (en) 2017-11-03
RU2014116577A (en) 2015-12-10
DK3272214T3 (en) 2020-03-02
NZ717130A (en) 2018-07-27
MX2014004896A (en) 2014-09-12
RS59997B1 (en) 2020-04-30
RS56330B1 (en) 2017-12-29
MX355726B (en) 2018-04-27
AU2021200438A1 (en) 2021-02-25
IN2014CN03892A (en) 2015-10-16
SMT202000114T1 (en) 2020-03-13
EP2770822B1 (en) 2017-06-14
CA2852962C (en) 2022-05-03
SMT201700437T1 (en) 2017-11-15
US20240365761A1 (en) 2024-11-07
AU2012327205B2 (en) 2016-01-14
CA2852962A1 (en) 2013-05-02
RS63220B1 (en) 2022-06-30
KR20180132970A (en) 2018-12-12
IL231895B (en) 2018-07-31
AU2016202317A1 (en) 2016-05-05
CY1125196T1 (en) 2025-03-28
US20130111616A1 (en) 2013-05-02
AU2016202317B2 (en) 2017-11-30
SG10201510056SA (en) 2016-01-28
CN108401986B (en) 2021-09-21
US8847005B2 (en) 2014-09-30
MX379060B (en) 2025-03-10
LT3590332T (en) 2022-08-10
IL243565A (en) 2017-10-31
ES2914374T3 (en) 2022-06-10
RU2018115251A (en) 2019-03-04
HK1250131A1 (en) 2018-11-30
SMT202200205T1 (en) 2022-07-21
US20190239496A1 (en) 2019-08-08
US20190239497A1 (en) 2019-08-08
PT2770822T (en) 2017-09-18
KR101926442B1 (en) 2018-12-12
SI2770822T1 (en) 2017-10-30
PL3590332T3 (en) 2022-06-13
CY1119283T1 (en) 2018-02-14
EP4052572B8 (en) 2026-01-07
SG11201400938UA (en) 2014-04-28
DK2770822T3 (en) 2017-09-25
SI3590332T1 (en) 2022-07-29
US10986822B2 (en) 2021-04-27
PL2770822T3 (en) 2017-11-30
HUE048511T2 (en) 2020-07-28
NZ623146A (en) 2016-06-24
JP2018019700A (en) 2018-02-08
JP6285361B2 (en) 2018-02-28
HRP20220616T1 (en) 2022-06-24
US9585373B2 (en) 2017-03-07
HUE034374T2 (en) 2018-02-28
PT3590332T (en) 2022-05-27
EP3272214A1 (en) 2018-01-24
US20170135329A1 (en) 2017-05-18
KR20140089558A (en) 2014-07-15
BR112014009941A2 (en) 2020-12-22
EP3272214B1 (en) 2019-11-27
LT2770822T (en) 2017-10-10
RU2018115251A3 (en) 2021-09-07
AU2018201402B2 (en) 2020-10-22
AU2018201402A1 (en) 2018-03-15
HK1196999A1 (en) 2015-01-02
US10219493B2 (en) 2019-03-05
US20210195878A1 (en) 2021-07-01
RU2660564C2 (en) 2018-07-06
KR102113108B1 (en) 2020-05-20
LT3272214T (en) 2020-03-10
CN104039133B (en) 2018-05-04
CN108401986A (en) 2018-08-17
AU2018201402C1 (en) 2021-05-06
CN104039133A (en) 2014-09-10
JP6652529B2 (en) 2020-02-26
BR112014009941B1 (en) 2022-11-29
IL231895A0 (en) 2014-05-28
SI3272214T1 (en) 2020-04-30
IL260209B (en) 2019-12-31
EP4052572A1 (en) 2022-09-07
PT3272214T (en) 2020-03-04
EP3590332A1 (en) 2020-01-08
PL3272214T3 (en) 2020-06-29
AU2012327205A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
SG10201909638UA (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
MY178723A (en) Genetically modified major histocompatibility complex mice
CY1121223T1 (en) Mice EXPRESSING A HUMANIZED MAJOR COMPLIANCE COMPLEX
EP4374690A3 (en) Mice expressing humanized t-cell co-receptors
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
EA202091566A1 (en) LIPID NANOPARTICLE CONTAINING NUCLEIC ACID AND ITS APPLICATION
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
IN2014CN03890A (en)
EP4635977A3 (en) Non-human animals having a humanized signal-regulatory protein gene
EA201592269A1 (en) METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS
MX2021000586A (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules.